top of page
The Professional Network for Healthcare Experts
Cipla licenses Qilu's Keytruda biosimilar for the US
The agreement gives Cipla exclusive US commercialisation rights to Qilu Pharmaceutical's pembrolizumab biosimilar candidate QL2107, referencing Keytruda.
nuaxia
4 days ago2 min read
Samsung Bioepis gains Japanese approval for intravenous Stelara biosimilar
Samsung Bioepis has received Japanese marketing approval for a 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara.
nuaxia
4 days ago1 min read
bottom of page